All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
XS-0422-LX75 | Anti-CCR7 (R7-11) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | R7-11 | Mouse | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX76 | Anti-CCR7 (R7-18) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | R7-18 | Mouse | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX77 | Anti-CCR7 (R7-47) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | R7-47 | Mouse | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX78 | Anti-CCR7 (121G12) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 121G12 | Humanized | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX79 | Anti-CCR7 (506E15) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 506E15 | Humanized | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX80 | Anti-CCR7 (684E12) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 684E12 | Humanized | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX81 | Anti-CCR7 (674J13) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 674J13 | Humanized | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX82 | Anti-CCR7 (MSM-R707) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | MSM-R707 | Human | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX83 | Anti-CCR7 (MSM-R735) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | MSM-R735 | Human | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX84 | Anti-CCR7 (6B5.1) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 6B5.1 | Human | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX85 | Anti-CCR7 (6B4.1) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 6B4.1 | Human | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX169 | Anti-CCR7 (R7-11) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | R7-11 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX170 | Anti-CCR7 (R7-18) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | R7-18 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX171 | Anti-CCR7 (R7-47) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | R7-47 | Mouse | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX172 | Anti-CCR7 (121G12) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | 121G12 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX173 | Anti-CCR7 (506E15) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | 506E15 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX174 | Anti-CCR7 (684E12) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | 684E12 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
XS-0422-LX365 | Anti-CCR7 (R7-11) h(CD28-41BB-CD3ζ) CAR, pMMLV | Human | R7-11 | Mouse | scFv-CD28-41BB-CD3ζ | Recombinant Moloney murine leukemia virus (MMLV) retroviral vector | T cell | ||
XS-0422-LX366 | Anti-CCR7 (R7-18) h(CD28-41BB-CD3ζ) CAR, pMMLV | Human | R7-18 | Mouse | scFv-CD28-41BB-CD3ζ | Recombinant Moloney murine leukemia virus (MMLV) retroviral vector | T cell | ||
XS-0422-LX367 | Anti-CCR7 (R7-47) h(CD28-41BB-CD3ζ) CAR, pMMLV | Human | R7-47 | Mouse | scFv-CD28-41BB-CD3ζ | Recombinant Moloney murine leukemia virus (MMLV) retroviral vector | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION